ArticleAdvanced functional materials2026
Nanodisc-Based Platform for HLA Antibody Identification.
Article in Advanced functional materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hybrid organic-inorganic CHJournal of molecular modeling · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
The presence of donor-specific antibodies (DSAs) is strongly associated with antibody-mediated rejection (AMR) and worse allograft outcomes. The current gold standard method for detecting anti-human leukocyte antigens (HLA) antibodies is based on the binding to HLA molecules, which are immobilized on beads. However, this assay may lead to the modification of the tertiary structure of the molecules and exposure of cryptic epitopes, thus resulting in aberrant false-positive and false-negative reactivity. With the increasing reliance on virtual crossmatching (comparing anti-HLA antibodies identified using the single antigen bead (SAB) assay to the donor HLA typing to identify DSAs) instead of a physical crossmatch, native and full-length HLA proteins are critical for accurate HLA antibody identification. In this study, we incorporate native and full-length HLA into phospholipid bilayer nanodiscs to form stable HLA-nanodisc (HLA-ND) complexes in a native-like membrane environment that maintains structure and prevents denaturation for anti-HLA antibody identification. Using these HLA-ND complexes immobilized on beads, we show successful DSA identification with serum from kidney transplant recipients. Furthermore, we introduce a novel bioluminescence-based bead-free homogeneous immunoassay for detecting anti-HLA antibodies using HLA-ND complexes. This platform has the potential to accurately detect multiple anti-HLA antibodies before and after solid organ transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.